China Overhauls ADR Reporting Regulations That Place Additional Responsibility On Drug Makers
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA released new guidelines for adverse drug reaction reporting May 24 that will dramatically increase the postmarket reporting responsibilities of manufacturers, distributors and hospitals